The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Services
  • Financial
  • Travel
  • Construction

Dr. Jeff Gelblum Provides Alzheimer's Treatment to Patients in the US and Abroad
The PennZone/10277342

Trending...
  • UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
  • 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
  • Tickeron Launches Next-Gen AI Corridor Bots: Consistent Exits for Stocks and ETFs
Alzheimer's Treatment
AVENTURA, Fla. - PennZone -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.

The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.

Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.

He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."

More on The PennZone
  • Holiday Decorations Most Likely to Cause Injuries
  • UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System
  • Zac Arbitman Elected As Co-Chair of Philadelphia Bar Association Federal Courts Committee
  • CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
  • BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary

Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.

Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy.  This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."

For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.

His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.

Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.

More on The PennZone
  • UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
  • Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
  • Twin Flame Visions Announces Surge in Traffic and Engagement Following Breakout Ad Performance
  • FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
  • Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California

Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."

He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.

About Jeffrey Gelblum, MD, FAAN

Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/

Contact
First Choice Neurology
***@fcneurology.net


Source: First Choice Neurology
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody
  • Compliance Is the Ticket to Entry: Legal Advisor Gabriela Moraes Analyzes RWA Securitization Paths Under Brazil's New Legislation
  • Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban
  • Spark Announces 2025 Design Award Winners
  • NEW Luxury Single-Family Homes Coming Soon to Manalapan - Pre-Qualify Today for Priority Appointments
  • Together We Dance Shines at Newtown Holiday Parade
  • Dominic Pace Returns to the NCIS Franchise With Guest Role on NCIS: Origins
  • Anderson Periodontal Wellness Attends 5th Joint Congress for Ceramic Implantology
  • UK Financial Ltd Completes Full Ecosystem Conversion With Three New ERC-3643 SEC-Ready Tokens As MCAT Deadline Closes Tonight
  • AI Real Estate Company Quietly Building a National Powerhouse: reAlpha Tech Corp. (N A S D A Q: AIRE)
  • Inkdnylon Expands National Uniform Embroidery Services
  • Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
  • Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
  • Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
  • Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
  • Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
  • Flower City Tattoo Convention Draws Record Attendance in Rochester, NY
  • KIKO NATION TOKEN (Official Release)
  • Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology
  • Psoriasis Drugs Market Poised to Hit 20 Billion Dollars in 2025 says SNS Research in Latest Report

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 652
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 222
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 107
  • Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • The Lashe® Announces Exclusive November Savings for Lash and Beauty Professionals
  • November is Lung Cancer Awareness Month: Screening Saves Aims to Increase Access to Lung Screenings in NC
  • Torch Entertainment Presents The Frozen Zoo

Similar on PennZone

  • Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
  • Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
  • Naturism Resurgence (NRE) Announces the World's First Standardised Stigma Measure (SSM) for Naturism
  • myLAB Box Expands, Becoming the First and Only At-Home Testing Company to Serve the Entire Family—Human and Furry—with New Pet Intolerance Test
  • Philadelphia Startup NoPlex Creates an ADHD/Neurodiversity-Focused Alternative to Productivity Apps
  • Coalition and CCHR Call on FDA to Review Electroshock Device and Consider a Ban
  • Anderson Periodontal Wellness Attends 5th Joint Congress for Ceramic Implantology
  • Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
  • Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us